## Kerstin Schütte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3221006/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors. Digestive Diseases, 2009, 27, 80-92.	1.9	406
2	The active bacterial assemblages of the upper GI tract in individuals with and without <i>Helicobacter</i> infection. Gut, 2018, 67, 216-225.	12.1	151
3	Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology, 2019, 157, 1081-1092.e3.	1.3	103
4	Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clinical Nutrition, 2015, 34, 1122-1127.	5.0	98
5	Markers for predicting severity and progression of acute pancreatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 75-90.	2.4	75
6	Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World Journal of Hepatology, 2014, 7, 139.	2.0	72
7	Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer, 2012, 1, 257-266.	7.7	48
8	Development and Validation of a Chronic Pancreatitis PrognosisÂScore in 2 Independent Cohorts. Gastroenterology, 2017, 153, 1544-1554.e2.	1.3	43
9	Clinical Characteristics and Time Trends in Etiology of Hepatocellular Cancer in Germany. Digestion, 2013, 87, 147-159.	2.3	34
10	Nutrition and Hepatocellular Cancer. Gastrointestinal Tumors, 2015, 2, 188-194.	0.7	33
11	Expression of zinc transporters ZIP4, ZIP14 and ZnT9 in hepatic carcinogenesis—An immunohistochemical study. Journal of Trace Elements in Medicine and Biology, 2018, 49, 35-42.	3.0	26
12	Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment. Gastrointestinal Tumors, 2014, 1, 84-92.	0.7	19
13	Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy. Digestive Diseases, 2019, 37, 161-169.	1.9	19
14	Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis. Digestion, 2011, 83, 275-282.	2.3	17
15	Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. Liver Cancer, 2020, 9, 771-786.	7.7	17
16	RiMINI – the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. Trials, 2016, 17, 111.	1.6	14
17	Expression analysis of zinc transporters in resting and stimulated human peripheral blood mononuclear cells. Biomedical Reports, 2014, 2, 217-222.	2.0	12
18	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma – a substudy of the SORAMIC trial. Acta Oncológica, 2020, 59, 1028-1035.	1.8	11

Kerstin Schütte

#	Article	IF	CITATIONS
19	The Pancreas: Causes for Malabsorption. Viszeralmedizin, 2014, 30, 190-197.	0.0	10
20	Prevalence of Helicobacter pylori Infection in Patients with Minimal Hepatic Encephalopathy. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 191-195.	0.9	9
21	Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors. World Journal of Gastroenterology, 2020, 26, 86-96.	3.3	8
22	Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. World Journal of Hepatology, 2020, 12, 1031-1045.	2.0	8
23	Analysis of lifestyle factors in patients with concomitant chronic pancreatitis and liver cirrhosis. Pancreatology, 2017, 17, 698-705.	1.1	7
24	Impact of healthy aging on active bacterial assemblages throughout the gastrointestinal tract. Gut Microbes, 2021, 13, 1966261.	9.8	7
25	Medical and Surgical Conditions for the Treatment of Malabsorption. Viszeralmedizin, 2014, 30, 149-149.	0.0	Ο
26	Reply. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 406-7.	0.9	0